Annual report pursuant to Section 13 and 15(d)

Organization and Description of Business (Details)

v3.24.0.1
Organization and Description of Business (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Oct. 30, 2023
USD ($)
Oct. 26, 2023
$ / shares
shares
Jul. 28, 2023
USD ($)
Mar. 15, 2023
shares
Mar. 03, 2023
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
$ / shares
Reverse stock split ratio       0.0667        
Preferred stock par value (in dollars per share)         $ 0.0001 $ 0.0001 $ 0.0001  
Number of fractional shares issued in connection with the Reverse Stock Split | shares       0        
Accumulated deficit | $           $ (380,971) $ (329,369)  
Common stock par value (in dollars per share)           $ 0.0001 $ 0.0001  
Warrant exercise price (in dollars per share)               $ 120.30
Proceeds from issuance of common shares - Registered Direct Offering | $ $ 4,400         $ 4,398 $ 0  
Offering costs for the issuance of common shares - Registered Direct Offering | $ $ 500         $ (443) $ 0  
Amended Asset Purchase Agreement | uBriGene                
Asset purchase agreements, base consideration | $     $ 6,000          
Asset purchase agreement, contingent consideration less severance obligation | $     $ 5,000          
Number of years after the closing date     2 years          
Securities Purchase Agreement                
Issuance of common shares (in shares) | shares   920,000            
Common stock par value (in dollars per share)   $ 0.0001            
Shares issued, price per share   $ 1.70            
Securities Purchase Agreement | Warrants                
Warrants issued | shares   1,668,236            
Warrant exercise price (in dollars per share)   $ 1.699            
Discount on price per share in warrant exercise   $ 0.001            
Private Placement | Warrants                
Warrants issued | shares   2,588,236            
Warrant exercise price (in dollars per share)   $ 1.58            
Warrants expiration term   5 years 6 months            
Offering price per share   $ 0.125            
Maximum                
Reverse stock split ratio         0.05      
Minimum                
Reverse stock split ratio         0.2      
Minimum | Amended Asset Purchase Agreement | uBriGene                
Issuance of equity securities | $     $ 10,000